KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Research & Development (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Research & Development readings, the most recent being $13.9 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 26.87% to $13.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.9 million, a 3.49% increase, with the full-year FY2025 number at $47.9 million, up 3.49% from a year prior.
  • Research & Development hit $13.9 million in Q4 2025 for Esperion Therapeutics, down from $14.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $33.0 million in Q4 2022 to a low of $7.2 million in Q2 2025.
  • Median Research & Development over the past 5 years was $19.9 million (2023), compared with a mean of $20.3 million.
  • Biggest five-year swings in Research & Development: plummeted 57.29% in 2024 and later surged 35.91% in 2025.
  • Esperion Therapeutics' Research & Development stood at $27.6 million in 2021, then rose by 19.62% to $33.0 million in 2022, then crashed by 46.29% to $17.7 million in 2023, then plummeted by 38.13% to $11.0 million in 2024, then increased by 26.87% to $13.9 million in 2025.
  • The last three reported values for Research & Development were $13.9 million (Q4 2025), $14.1 million (Q3 2025), and $7.2 million (Q2 2025) per Business Quant data.